Topics

US FDA Says Data Integrity Remains Challenging For API Manufacturers

11:35 EST 4 Dec 2019 | SCRIP

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

      

Related Stories

 

Original Article: US FDA Says Data Integrity Remains Challenging For API Manufacturers

NEXT ARTICLE

More From BioPortfolio on "US FDA Says Data Integrity Remains Challenging For API Manufacturers"

Quick Search